[\(^{11}\text{C}\)]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease

Jelle van den Ameele, MD, PhD, Young T. Hong, PhD, Roido Manavaki, PhD, Antonina Kouli, PhD, Heather Biggs, Zoe MacIntyre, PhD, Rita Horvath, MD, Patrick Yu-Wai-Man, PhD, FRCOphth, Evan Reid, PhD, FRCP, Caroline H. Williams-Gray, PhD, FRCP, Ed T. Bullmore, PhD, FRCPsych, FMedsoc, Franklin I. Aigbirhio, DPhil, Tim D. Fryer, PhD, and Patrick F. Chinnery, PhD, FRCsych, FMedsci

Neurology® 2021;96:e2761-e2773. doi:10.1212/WNL.0000000000012033

Abstract

Objective
To explore the possibilities of radioligands against the mitochondrial outer membrane translocator protein (TSPO) as biomarkers for mitochondrial disease, we performed brain PET-MRI with \(^{11}\text{C}\)]PK11195 in 14 patients with genetically confirmed mitochondrial disease and 33 matched controls.

Methods
Case–control study of brain PET-MRI with the TSPO radioligand \(^{11}\text{C}\)]PK11195.

Results
Forty-six percent of symptomatic patients had volumes of abnormal radiotracer binding greater than the 95th percentile in controls. \(^{11}\text{C}\)]PK11195 binding was generally greater in gray matter and significantly decreased in white matter. This was most striking in patients with nuclear TYMP or mitochondrial m.3243A>G MT-TL1 mutations, in keeping with differences in mitochondrial density seen postmortem. Some regional binding patterns corresponded to clinical presentation and underlying mutation, even in the absence of structural changes on MRI. This was most obvious for the cerebellum, where patients with ataxia had decreased binding in the cerebellar cortex, but not necessarily volume loss. Overall, there was a positive correlation between aberrant \(^{11}\text{C}\)]PK11195 binding and clinical severity.

Conclusion
These findings endorse the use of PET imaging with TSPO radioligands as a noninvasive in vivo biomarker of mitochondrial pathology.

Classification of Evidence
This study provides Class III evidence that brain PET-MRI with TSPO radioligands identifies mitochondrial pathology.

Class of Evidence
Criteria for rating therapeutic and diagnostic studies
NPub.org/coe
Mitochondrial diseases have emerged as among the most common inherited neurologic disorders and together affect about 1 in 5,000 of the UK population. Mitochondrial diseases are progressive multisystem disorders that can present at any stage in life and often affect the CNS. Curative treatments are lacking and management is largely based on symptomatic therapies and maximizing quality of life. Although there are a growing number of agents being tested in preclinical animal models, few studies have demonstrated efficacy in humans. This reflects in part the lack of objective clinical biomarkers that show change over a practical timescale or allow subgroup characterization, essential prerequisites to provide evidence of efficacy in a heterogeneous rare disease cohort.

The isoquinoline PK11195 selectively binds to the 18 kDa translocator protein (TSPO), thought to be involved in cholesterol transport across the outer mitochondrial membrane. [11C]PK11195 PET imaging of TSPO has mainly been used as a marker of neuroinflammation and microglial activation, based on strong radiotracer accumulation in ischemic and inflammatory brain lesions. However, it is increasingly appreciated that TSPO ligand binding as a measurement of microglial activation is an oversimplification, and altered TSPO abundance is likely affected by many other disease-specific processes. Given its localization to mitochondria, we sought to explore the utility of [11C]PK11195 PET imaging of TSPO as an in vivo biomarker of mitochondrial pathology in the brain, with a view to monitoring progression of mitochondrial disease.

Methods

Classification of Evidence

The primary research objective was to explore possibilities of TSPO radioligands as in vivo noninvasive biomarkers for mitochondrial disease, based on the localization of TSPO to the outer mitochondrial membrane in all cell types of the brain. This study provides Class III evidence that brain PET-MRI with TSPO radioligands identifies mitochondrial pathology.

Standard Protocol Approvals, Registrations, and Patient Consents

Patients with genetically confirmed mitochondrial disease were recruited through a specialist mitochondrial disease clinic at Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, United Kingdom. Fifteen patients consented to undergo PET-MRI. The scan of patient 13 was cancelled because of an upper respiratory tract infection and this patient was excluded from the analysis. Human phenotype ontology terms for each patient were assigned based on electronic health records. Modified Rankin Scale (mRS) score and Scale for the Assessment and Rating of Ataxia (SARA) were calculated based on available clinical examinations in the electronic health records. The research protocol was approved by a National Research Ethics Service committee (REC ID: 16/LO/2093). The healthy control cohort comprised subjects from projects in depression (n = 25; REC ID: 15/EE/0092) and Parkinson disease (n = 8; REC ID: 16/EE/0445; recruited via the NIHR Cambridge Bioresource) that used the same data acquisition protocol on the same PET-MRI scanner. All these projects received approval from the Administration of Radioactive Substances Advisory Committee and all participants provided written informed consent in accordance with the Declaration of Helsinki.

PET Data Acquisition

All participants underwent PET and MRI in a single session on a GE Signa PET-MR scanner (GE Healthcare), which can simultaneously acquire PET and 3T MRI data. [11C] PK11195 was injected over approximately 30 seconds and list-mode PET data were acquired for 75 minutes. The median (interquartile range [IQR]) injected activity was 397 (62) MBq with corresponding injected mass values of 3.8 (3.8) μg. Injected activity per unit body weight (MBq/kg) and injected mass were not significantly different between the mitochondrial disease and control groups. Attenuation correction included the use of a multisubject atlas method and improvements to the MRI brain coil component. Other data corrections (dead time, randoms, normalization, scatter, sensitivity, and decay) were as implemented on the scanner. Dynamic sinograms were reconstructed into 128 × 128 × 89 arrays (2.0 × 2.0 × 2.8 mm voxel size) using time-of-flight ordered subsets expectation maximization, with 6 iterations, 16 subsets, and no smoothing. Brain T1 and T2 MRI acquired as part of the protocol were reviewed as part of routine clinical radiology reporting.

Image Processing and Kinetic Analysis

Each emission image series was aligned using SPM12 (filion.ucl.ac.uk/spm/software/spm12/) to ameliorate the effect of motion, then rigidly registered to the high-resolution (isotropic 1.0 mm), volumetric T1-weighted MRI acquired during PET data acquisition. Using a version of the Hammersmith atlas (brain-development.org) defined on the ICBM 152 2009a...
### Table Overview of All Patients With Mitochondrial Disease

| ID | Age, y | Sex | Affected gene | Mutation | mRS disability scale | SARA ataxia scale | Clinical syndrome | Clinical phenotype (HPO terms) | Main MRI findings |
|----|--------|-----|---------------|----------|----------------------|------------------|------------------|--------------------------------|------------------|
| 1  | 59     | M   | SPG7          | c.1053dup; c.1529C>T | 2        | 9                  | SCA             | Lower limb spasticity, progressive gait ataxia, diabetes mellitus, predominantly lower limb lymphedema, obstructive sleep apnea, chronic fatigue, urinary urgency | Cerebellar atrophy affecting the vermis and both hemispheres |
| 2  | 26     | M   | MT-ND4        | m.11778G>A | 2        | —                 | LHON            | Optic neuropathy | Normal report |
| 3  | 54     | M   | MT-TL1        | m.3243A>G | 4        | 9                  | MELAS           | Myoclonus, obsessive-compulsive behavior, depression, muscle cramps, myalgia, chronic constipation, ataxia, diabetes mellitus, stroke-like episode, dysarthria | Nonspecific small areas of increased T2 signal intensity in the left corona radiata extending into the body of the corpus callosum and in the subcortical white matter of the superior part of the right insula |
| 4  | 46     | F   | MT-ND6        | m.14484T>C | 3        | —                 | LHON            | Optic neuropathy, progressive peripheral neuropathy | Generalized brain volume loss greater than expected for age |
| 5  | 34     | M   | MT-ND6        | m.14487T>C | 4        | —                 | LHON/PME        | Optic neuropathy, myoclonus, seizure, bilateral ptosis | Cortical/subcortical foci of abnormal single intensity in the medial aspect of the left parietal and occipital lobes and in the right parietal lobe |
| 6  | 60     | F   | MT-ND6        | m.14487T>C | 0        | —                 | Asymptomatic    | Nonspecific white matter hyperintensities in both central semiovale, most likely of vascular origin |
| 7  | 35     | M   | MT-ND4        | m.11778G>A | 2        | —                 | LHON            | Optic neuropathy | Normal report |
| 8  | 34     | F   | MT-ATP6       | m.8993T>G | 2        | 4                  | NARP            | Ataxia, chronic pain, chronic fatigue, depression, peripheral neuropathy | Slight prominence of the cerebellar CSF spaces |
| 9  | 64     | M   | MT-TL1        | m.3243A>G | 2        | —                 | CPEO/MIDD       | Bilateral ptosis, external ophthalmoplegia, diabetes, peripheral neuropathy | There is generalized prominence of the ventricles and sulci in keeping with cerebral and cerebellar atrophy; no focal parenchymal lesion |
| 10 | 46     | M   | SPG7          | c.861+2dupT; c.1045G>A | 2        | 7                  | SCA             | Progressive gait ataxia, lower limb spasticity, myotonia (this patient also carried an autosomal dominant CLCN1 mutation) | Normal report |
| 11 | 41     | F   | TYMP          | c.401C>A; c.845G>A | 3        | —                 | MNGIE           | Chronic fatigue, weight loss, peripheral neuropathy, chronic diarrhea, abdominal cramps, diffuse white matter abnormalities, limb muscle weakness | Diffuse increased intensity on T2 in the white matter of both cerebral hemispheres also affecting external capsules, posterior limbs of internal capsule, and both thalamic patchy high intensity in the brainstem |
| 12 | 40     | M   | SPG7          | c.1529C>T; c.1727C>G | 3        | 13                 | SCA             | Postural instability, gait imbalance, urinary urgency, spasticity, cerebellar atrophy | Mild irregularity of the bodies of both lateral ventricles suggesting chronic white matter volume loss; mild cerebellar volume loss |
| 14 | 39     | M   | POLG          | c.647C>T; c.2243G>C | 2        | 12                 | SANDO           | Ataxia, bilateral ptosis, external ophthalmoplegia, peripheral neuropathy | Normal report |

Continued
T1 template with modified posterior fossa regions, 33 regions of interest (ROIs) including aggregated regions for frontal, parietal, occipital, and temporal lobes; cingulate; and cerebellum were delineated on the T1-weighted MRI of each participant using the inverse of spatial normalization parameters determined with SyN implemented in the Advanced Normalisation Tools software package (picsl.upenn.edu/software/ants/). Regional time-activity curves were extracted following the application of geometric transfer matrix (GTM) partial volume correction (PVC) to each of the dynamic PET images. The GTM step was performed twice, with the ROIs in each case multiplied by a gray or white matter binary mask (>50% on the SPM12 probability map smoothed to PET spatial resolution). Multiple additional regions were defined to provide full spatial coverage for GTM PVC.

To quantify [11C]PK11195 binding, nondisplaceable binding potential (BPND) was determined, both regionally and at the voxel level, using a basis function implementation of a simplified reference tissue model that includes correction for vascular binding, with the reference tissue defined using supervised cluster analysis. For the gray and white matter masked ROIs, the reference tissue used corresponded to the gray matter and white matter kinetic class, respectively. To provide a global BPND metric for both gray matter and white matter, the volume-weighted average of the BPND values in the corresponding ROIs was determined. Similarly, 2 BPND maps were produced per subject using either the gray matter or white matter reference tissue input. Prior to parametric mapping, the dynamic PET images were smoothed with a 4 mm full width at half maximum (FWHM) Gaussian. To facilitate voxel-wise statistical analysis, BPND maps were normalized to ICBM 152 2009a template space using the parameters obtained with SyN spatial normalization of the coregistered T1-weighted MRI. All images are shown in radiologic format (i.e., the left of the brain is on the right of the image).

### Statistical Analysis

#### Demographics

The age and sex distributions of the control and mitochondrial disease groups were compared using the Mann-Whitney U and Fisher exact tests, respectively.
class. Correlations of global voxel fractions with clinical severity scales were calculated as Pearson correlation coefficient in R.

**Data Availability**
The raw data that support the findings of this study are available on request from the corresponding author. All patient \( \log_{10}(p) \) maps are displayed in appendix e-1 (available from Dryad, doi.org/10.5061/dryad.zs7h44j7s) as overlay of \( \log_{10}(p) \) on the ICBM 152 2009a T1 MRI template for voxels with significantly increased (top) or decreased (bottom) binding potential (\( p < 0.05; p \leq 0.001 \) in red) for each patient compared to controls. The scale shown for patient 1 applies for all other images.

**Results**

**Patient Characteristics**
Fourteen patients with genetically confirmed mitochondrial disease underwent PET-MRI. Demographics, clinical characteristics, mutations, and MRI findings of all patients are described in the table. mtDNA haplotypes were not available. Patient 6 is an asymptomatic family member of patient 5, with low heteroplasmy levels of the MT-ND6 m.14487T>C mutation (as previously described in reference 28) and was excluded from statistical analyses of affected individuals. The control dataset included 33 healthy volunteers whose age and sex distributions matched those of the patient group (\( p = 0.826 \) for age; \( p = 0.185 \) for sex; figure e-1 available from Dryad, doi.org/10.5061/dryad.zs7h44j7s).

**Mitochondrial Disease Affects \([11C]PK11195\) Binding in the Brain**
We compared radiotracer binding characteristics in the gray and white matter across the brain between patients and controls. In gray matter, global BP\(_{\text{ND}}\) was comparable between both groups (\( p = 0.516 \)), with the values for most patients falling within the control range (figure 1A). In contrast, across white matter, global BP\(_{\text{ND}}\) was lower in patients with mitochondrial disease than in controls (\( p = 0.004 \)), mainly determined by a large decrease in BP\(_{\text{ND}}\) in 2 or 3 of the patients (figure 1B; see below).

Across patients and different regions of the brain, the volume of significantly increased or reduced BP\(_{\text{ND}}\) was highly heterogeneous, but overall, the proportion of gray or white matter with significantly (\( p < 0.001 \)) increased or reduced BP\(_{\text{ND}}\) was significantly higher in patients than in controls (gray matter: \( p = 0.025 \) for voxels with increased BP\(_{\text{ND}}\); white matter: \( p = 0.028 \) for increased and \( p = 0.024 \) for decreased BP\(_{\text{ND}}\) (figure 1, C–F; figure e-2 available from Dryad, doi.org/10.5061/dryad.zs7h44j7s). For 6/13 (46%) symptomatic patients, the proportion of voxels with significantly increased or decreased BP\(_{\text{ND}}\) was higher than the 95th percentile of controls. Patient 6, an asymptomatic carrier, had the lowest volume of abnormal binding (0.1 mL). Together, these findings indicate that, although mitochondrial disease does not cause a homogeneous and reproducible change in BP\(_{\text{ND}}\), it can significantly affect \([11C]PK11195\) binding in large parts of the brain in individual patients.

**Regional \([11C]PK11195\) Binding Characteristics**
To assess whether \([11C]PK11195\) binding in specific brain regions would be preferentially affected by mitochondrial dysfunction, BP\(_{\text{ND}}\) was determined in 12 white matter (figure 2A) and 17 gray matter ROIs (figure 2B). Consistent with the decrease in global BP\(_{\text{ND}}\) in white matter (figure 1B), 11/12 white matter ROIs (not midbrain; figure 2A) showed

---

**Figure 1 Mitochondrial Disease Affects \([11C]PK11195\) Binding Potential**

(A, B) Global \([11C]PK11195\) nondisplaceable binding potential (BP\(_{\text{ND}}\)) in (A) gray matter or (B) white matter for each control (green) and patient with mitochondrial disease (blue). (C, D) Fraction of voxels in (C) gray matter or (D) white matter for each individual from the control (green) or mitochondrial disease group (blue) where BP\(_{\text{ND}}\) was significantly different (\( p < 0.001 \)) from the control population at the voxel level. Y-axis is log-transformed. \( p \) Values for A–D are calculated by age- and sex-corrected linear regression. (E, F) Average of individual T statistic maps for (E) controls and (F) patients with mitochondrial disease compared to the control cohort, overlaid on the ICBM 152 2009a T1 MRI template.
decreased radiotracer binding in patients with mitochondrial disease. However, when corrected for multiple comparisons, these region-specific white matter differences did not reach significance. In contrast, in gray matter, following correction for multiple comparisons, regional BPND was significantly lower in the cerebellar gray matter of patients with mitochondrial disease compared to controls ($p=0.001$), while BPND in the hippocampus ($p=0.002$) and substantia nigra ($p=0.001$) were significantly increased (figure 2B).

**Decreased [$^{11}$C]PK11195 BP in the Cerebellum of Patients With Ataxia**

We examined whether the significant differences observed in gray matter of the cerebellum, hippocampus, and substantia nigra were due to specific mutations or clinical characteristics (figure 3). The most striking outlier was patient 4 with Leber hereditary optic neuropathy (LHON) and peripheral neuropathy due to a $MT$-ND6 m.14484T>C mutation, where we observed a strong increase in binding in both hippocampi (Figure 3, A and B). This patient had generalized brain atrophy as reported on MRI, but no clinical signs or symptoms suggestive of hippocampal dysfunction (table). Increased BPND values in the substantia nigra (figure 3C) also did not correlate with the presence of parkinsonism or other extrapyramidal symptoms (table), despite these symptoms being part of the clinical spectrum in mitochondrial disease.$^{29}$

Interestingly, the 2 patients with the lowest regional BPND in cerebellar gray matter both presented with ataxia (patient 1 with an SPG7 mutation and patient 8 with an $MT$-ATP6 mutation) (figure 3D). Subgroup analysis of all patients with ataxia (7/13) showed a significant decrease in regional BPND ($p=0.001$) compared to controls (figure 3D). This was not always accompanied by atrophy on brain MRI (table), suggesting that clinically relevant changes in [$^{11}$C]PK11195 binding patterns may precede or occur independently of gross structural abnormalities.

**Regional Differences in Decreased [$^{11}$C]PK11195 Binding in White Matter Caused by $MT$-TL1 and TYMP Mutations**

The decrease in white matter global BPND in patients with mitochondrial disease was mostly driven by 3 individuals (patients 3, 9, and 11) whose white matter BPND was severely reduced (see figure 1B). Patients 3 and 9 were respectively...
diagnosed with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness (MIDD) caused by a heteroplasmic MT-TL1 (m.3243A>G) mutation; patient 11 had mitochondrial neurogastrointestinal encephalopathy (MNGIE) caused by compound heterozygous TYMP mutations (table).

The decrease in white matter BPND was most striking in the frontal and parietal lobes of the forebrain, where all 3 patients had relatively low radiotracer binding (figure 4A), and a large fraction of the tissue was composed of voxels with significantly decreased [11C]PK11195 BPND compared to controls (figure 4, C–E and I–K). For patients 3 and 9 with MT-TL1 mutations, BPND was also low in most other white matter ROIs (figure 4A, B, M, and N), but only patient 3 had a few small white matter lesions on MRI (table; figure 4C) and the MRI of patient 9 only showed generalized atrophy but no leukoencephalopathy. Patient 11 with TYMP mutations had widespread white matter abnormalities on MRI in the 4 lobes of both hemispheres and brainstem, compatible with MNGIE-related leukoencephalopathy (figure 4I and L). However, in contrast to the strong reductions in BPND in the frontal and parietal lobes (figure 4, A and K), radiotracer binding was normal or increased in the white matter of the temporal lobe and posterior fossa (figure 4, A, B, M, and N), as well as in deeper brain structures like pallidum and midbrain, and in the cerebellar white matter. Together, these highly variable binding patterns between brain regions and individuals indicate that different parts of the brain, and even different types of white matter, may respond in distinct ways to mitochondrial dysfunction, also when cells are affected by the same nuclear or mitochondrial gene mutation.

Asymmetry of [11C]PK11195 Binding

Many of the [11C]PK11195 PET images showed asymmetric signal changes in specific regions of the brain (figure 5), without obvious corresponding abnormalities on the corresponding MRI. The most obvious examples of asymmetric radiotracer binding were in the cerebral cortex (frontal cortex in patient 1 with SPG7 mutation; occipital cortex in patient 3 with an MT-TL1 mutation; figure 5, A and C), the basal ganglia (patient 8, MT-ATP6 mutation; figure 5E), or the cerebellum (patient 7 with an MT-ND4 mutation; figure 5G). Asymmetric signal change was not clearly related to clinical presentation, as illustrated by the increased signal in

Figure 3 Increased and Decreased [11C]PK11195 Binding Potential in Gray Matter Regions
the right lateral cerebellar hemisphere of a patient with LHON (patient 7; figure 5G) who was otherwise asymptomatic (table).

Fraction of Voxels With $[^{11}C]$PK11195 Binding Change Correlates With Clinical Severity

We used the mRS to measure clinical disability in the 13 patients with symptomatic mitochondrial disease and the SARA to quantify the degree of ataxia. There was a significant positive correlation ($r = 0.58; p = 0.037$) between mRS and the fraction of voxels across all ROIs (gray and white matter) with a significant change (increase or decrease) in $[^{11}C]$PK11195 binding (figure 6A): patients with a larger part of their brain affected by abnormal binding (either increased or decreased) had a higher chance of being more disabled as measured by the mRS. This was most striking within groups of patients with the same mutation (i.e., patients with the m.3243A>G MT-TL1 mutation or the m.14487T>C MT-ND6 mutation), where clinical symptoms as measured by mRS were always worse in those patients with a higher fraction of voxels with changed binding (figure 6, B, D, J, K) and posterior fossa (C, H, M, N), together with the corresponding T2 MRI (C, F, I, L) for patients 3 and 11.

Discussion

We describe $[^{11}C]$PK11195 PET brain imaging of the mitochondrial outer membrane protein TSPO in a group of representative patients with genetically confirmed mitochondrial disease. Our results demonstrate a correlation between the degree of abnormal radiotracetracer binding across the brain and clinical severity in symptomatic patients. In addition, we found that regional binding abnormalities may correspond to clinical presentation, are mutation-specific, and mostly occur in the absence of obvious structural changes on brain MRI.

$[^{11}C]$PK11195 PET imaging of TSPO is widely used as a marker of neuroinflammation, due to its accumulation in activated microglia in the brain. Although this is probably valid for CNS disorders where the primary disease process is related to inflammation, TSPO abundance and radiotracer binding are likely to be differentially affected in many other noninflammatory conditions. In particular, a decrease in radiotracer binding, as previously observed in autism spectrum disorder, schizophrenia, or inactive multiple sclerosis lesions, is more difficult to reconcile with microglial activity or inflammation. Given its localization to mitochondria in all cell types of the CNS, it is conceivable that TSPO abundance in the brain is affected by pathologic changes associated with mitochondrial disease.
The 14 patients with mitochondrial disease had mutations in the mitochondrial or nuclear genomes causing a range of mitochondrial syndromes at various stages of their disease course (table), thus providing a heterogeneous, but representative case series. For 6 patients, the volume of abnormal \textsuperscript{11}C PK11195 radiotracer binding across the brain exceeded the 95th percentile of the control population. In contrast to neuroinflammatory disorders, radiotracer binding was not simply increased, but patients and brain regions had variable patterns of reduced or enhanced BPND. This indicates that mitochondrial disease is not necessarily accompanied by inflammation and microglial activity. These findings are in line with previous neuropathologic studies that only showed microglial proliferation in active stroke-like lesions in the temporal and occipital cortex of patients with MELAS,	extsuperscript{33} or late stages of Leigh syndrome lesions,	extsuperscript{34} but not elsewhere in the brain.	extsuperscript{2,35,36}

Mitochondrial dysfunction frequently results in increased mitochondrial biogenesis and a redistribution of mitochondria within the cell. We found that, on average, in patients with mitochondrial disease, white matter was more likely to show reduced rather than increased TSPO abundance compared to controls. White matter is mostly composed of long-range axons and has relatively few cell bodies. This decrease in radiotracer binding in axon-rich regions of the brain is reminiscent of studies in cell culture\textsuperscript{37} and model organisms\textsuperscript{38,39} where genetic perturbation of mitochondrial function was associated with a reduction in mitochondrial density in the distal axons of neurons. In gray matter, where neuronal cell bodies are located, binding was more variable and frequently increased. Interestingly, in the soma of dopaminergic neurons of the substantia nigra, a gray matter region in the midbrain where we observed a significant increase in average BPND (figures 2B and 3C), elevated levels of mitochondrial protein expression have been found to coincide with respiratory chain deficiencies due to an m.8344A>G mutation or a single mtDNA deletion,	extsuperscript{40} and mtDNA copy number was shown to increase with aging.	extsuperscript{41} This suggests that increased radiotracer binding in gray matter regions of the brain could at least in part be explained by increased mitochondrial biogenesis with accumulation of mitochondria in the neuronal cell bodies. This is consistent with the “sick mitochondrion” hypothesis, in which preferential replication of defective mitochondria is thought to explain ragged-red fibers in skeletal muscle.	extsuperscript{42-44}

Our findings indicate that the same mechanism may be at play in the brain. However, it is also possible that TSPO expression is independent of mitochondrial mass,	extsuperscript{45} and other cell types can also be affected, such as oligodendrocytes,	extsuperscript{46} or endothelium and smooth muscle cells of the cerebral vasculature.\textsuperscript{2,36} More extensive postmortem studies of mitochondrial mass and its relation to TSPO expression in the brain of patients with mitochondrial disease are required to fully support TSPO PET imaging as a novel noninvasive in

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure5}
\caption{Asymmetry of \textsuperscript{11}C PK11195 Binding}
\end{figure}
vivo measure of mitochondrial density in the brain. Alternatively, it would be interesting to explore the validity of TSPO PET imaging of muscle, where neuropathologic correlates of mitochondrial biogenesis are more readily available.

CNS involvement in metabolic disorders such as mitochondrial disease is often thought to be bilateral and symmetric, with generalized brain or cerebellar atrophy, widespread white matter changes, or bilateral, symmetric basal ganglia lesions.4,42 Even lateralized parkinsonism symptoms are not necessarily accompanied by asymmetric lesions on brain MRI or dopamine transport (DAT-SPECT) imaging.45 Interestingly, many of our patients had large regions of asymmetric binding abnormalities, with otherwise normal or symmetric MRI. In the cerebellum of patients with cerebellar ataxia, we found significant reductions in [11C]PK11195 binding using regional BPND values corrected for atrophy with GTM partial volume correction. Although many patients had some degree of cerebellar atrophy, reduced binding was even observed in the absence of overt cerebellar atrophy as reported on MRI. Postmortem studies in patients with ataxia due to mitochondrial disease have found a reduction in mitochondrial density in the cerebellar cortex, possibly related to microscopic neuronal loss.46 Together, these findings suggest that changes in [11C]PK11195 binding may precede structural MRI abnormalities and could be more sensitive than MRI at detecting reduced neuronal or mitochondrial density.

This study used the prototypic TSPO PET tracer [11C]PK11195. Compared to higher-affinity second-generation TSPO PET tracers, such as [11C]PBR28 and [11C]DPA-713, [11C]PK11195 has lower transport into brain tissue and a lower ratio specific to nonspecific binding (except for low affinity binders), resulting in BPND estimates of inferior statistical quality.49 However, [11C]PK11195 has the advantage of obviating the need to divide the participants into binding affinity groups (high, mixed, low) driven by a polymorphism in the TSPO gene.50 In a small cohort, such as in this study, avoiding this subdivision is particularly advantageous. However, if much larger, multicenter studies employing TSPO

Figure 6 Clinical Severity Correlates With Changes in [11C]PK11195 Binding

(A–C) Correlation between score on the (A, B) modified Rankin Scale (mRS) or (C) Scale for the Assessment and Rating of Ataxia (SARA) and the fraction of the brain (A and B) or cerebellum (C) where nondisplaceable binding potential (BPND) was significantly ($p < 0.001$) different from the control population for all 13 symptomatic patients with mitochondrial disease (A; r = 0.58; p value 0.037) or only for those patients with MT-TL1 (B) or POLG (C) mutations. (D–G) Overlay of $-\log_{10}(p$ value) for voxels with significantly increased (patient $>$ controls) or decreased (patient $<$ controls) [11C]PK11195 BPND ($p < 0.05$; $p \leq 0.001$ in red) on the ICBM 152 2009a T1 MRI template at regular dorso-ventral intervals across the brain (D and E) or at the level of the cerebellum (F and G). ROI = region of interest.
PET imaging are conducted in the future on patients with mitochondrial disease, the cost, access to tracers or equipment, and reproducibility of imaging in different settings all will have to be taken into account, and the increased sensitivity offered by more accessible and cost-effective second-generation TSPO PET tracers labeled with fluorine-18 may be considered.

\[^{[11C]}\text{PK11195}\] BP\textsubscript{ND} was quantified using reference tissue kinetic modeling, which requires a key additional assumption compared to gold standard kinetic modeling with an arterial input function; namely, that the reference tissue input is devoid of specific binding. Reference tissue inputs produced by the method employed in this study (supervised cluster analysis) were shown to have lower total distribution volumes than those obtained from the most commonly used anatomical reference tissue, the cerebellum.\textsuperscript{27} This supports the notion that reference tissue inputs from supervised cluster analysis better approximate the ideal situation of a null contribution from specific binding. To further improve the accuracy of the BP\textsubscript{ND} estimates, the reference tissue model incorporates correction for vascular signal, including binding to endothelial TSPO receptors.\textsuperscript{28} Although reference tissue modeling of \[^{[11C]}\text{PK11195}\] PET data with a reference tissue input from supervised cluster analysis has been validated with arterial input function kinetic modeling,\textsuperscript{27,51} ideally this validation process should be extended to patients with mitochondrial disease.

Research into novel therapies of mitochondrial disease has been hampered by the lack of useful noninvasive biomarkers that measure disease severity and progression.\textsuperscript{9,10} Our findings suggest that PET imaging of TSPO has potential as a noninvasive biomarker of disease progression for CNS involvement in mitochondrial disease, given that binding abnormalities across the entire brain were significantly correlated with clinical severity. When we restricted the analysis to patients with the same genetic mutation, patients with more severe clinical presentations always had more extensive \[^{[11C]}\text{PK11195}\] binding abnormalities than their less disabled counterparts. Our cohort was too small and heterogeneous to demonstrate strong correlations between specific symptoms and regional binding characteristics. However, for patients with ataxia, symptom severity was clearly related to reduced radiotracer binding in the cerebellum. Larger natural history studies are needed that measure disease progression together with whole-brain and region-specific radiotracer binding, including in genetically homogeneous patient cohorts, to confirm the validity of TSPO PET as a reliable biomarker for interventional studies in thus far incurable mitochondrial diseases.

**Acknowledgment**
The authors thank the patients and healthy volunteers for their participation, the staff of the WBIC Radiopharmaceutical Unit for the production of \[^{[11C]}\text{PK11195}\], the WBIC radiographers for data acquisition, and the NIHR Cambridge BioResource volunteers and staff for their contributions; and the National Institute for Health Research and NHS Blood and Transplant.

**Study Funding**
J. van den Ameele is a Wellcome Clinical Research Career Development Fellow (219615/Z/19/Z) and receives support from the Medical Research Council (MRC) Mitochondrial Biology Unit (MC_UU_00015/10). R. Manavaki is supported by the NIHR Cambridge Biomedical Research Centre. R. Horvath is supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the MRC (UK, MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and the Newton Fund (UK/Turkey, MR/N027302/1). P. Yu-Wai-Man is supported by a Clinician Scientist Fellowship Award (G1002570) from the MRC (UK) and receives funding from Fight for Sight (UK), the Isaac Newton Trust (UK), the Addenbrooke’s Charitable Trust, the National Eye Centre (UK), the UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration, and the NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. C.H. Williams-Gray holds a RCUK/UKRI Research Innovation Fellowship awarded by the MRC (MR/R007446/1) and received grant support for this work from the Evelyn Trust. E. Bullmore is a UK NIHR Senior Investigator. P. Chinnery is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z) and a UK NIHR Senior Investigator, who receives support from the MRC Mitochondrial Biology Unit (MC_UU_00015/9), the MRC International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer’s Society Project grant (AS-PG-18b-022), and the NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

**Disclosure**
The authors report no competing interests relevant to the submitted manuscript. Go to Neurology.org/N for full disclosures.

**Publication History**
Received by Neurology November 17, 2020. Accepted in final form March 4, 2021.

**Appendix Authors**

| Name                  | Location               | Contribution                                      |
|-----------------------|------------------------|---------------------------------------------------|
| Jelle van den Ameele, MD, PhD | University of Cambridge, UK | Data acquisition, analysis, and interpretation; recruitment of patients/controls; drafted the manuscript for intellectual content |
| Young T. Hong, PhD    | University of Cambridge, UK | Data acquisition, data analysis                   |

*Continued*
References

1. Gorman GS, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77:753-759.

2. Lax NZ, Gorman GS, Turnbull DM. Review: central nervous system involvement in mitochondrial disease. Neuropathol Appl Neurol Biol. 2017;43:102-118.

3. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disorders. Neuromuscul Disord. 2020;31:1078-1090.

4. Pfeffer G, Majumdar K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012;4:CD004426.

5. Pirinen E, Auranen M, Khan NA, et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 2020;31:1078-1090.

6. Steele H, Gomes-Duran A, Pyle A, et al. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol Med. 2020;12:e11899.

7. Steele HE, Horvath R, Lyon JJ, Chinnery PF. Monitoring clinical progression with mitochondrial disease biomarkers. Brain. 2017;140:2530-2540.

8. Karas A, Haas R, Golder A, Vockley J, Douglas Weaver W, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212-e1221.

9. Stebbins E, Williams-Gray M, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Neuropathol Appl Neurol Biol. 2017;43:102-118.

10. Benavides J, Fage D, Carter C, Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987;421:167-172.

11. Ramsay SC, Weiller C, Myers R, et al. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet. 1992;339:1054-1055.

12. Zavala F, Lemanf M. Benzodiazepines and PK 11195 exert immunomodulating activities by binding on a specific receptor on macrophages. Ann NY Acad Sci. 1987;496:240-249.

13. Jaremko L, Jaremko M, Giller K, Becker S, Zackrzesniak M. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Scienc. 2014;343:1363-1366.

14. Papadopoulos V, Baraldi M, Gualtate TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402-429.

15. Anholt RRH, Pedersen PL, De Souza EB, Snyder SH. The peripheral-type benzodiazepine receptor: localization to the mitochondrial outer membrane. J Biol Chem. 1986;261:576-583.

16. Rupprecht R, Papadopoulos V, Rammos G, et al. Translocator protein (18 kDa) (TSPo) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Disc. 2010;9:971-988.

17. Benavides J, Fage D, Carter C, Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987;421:167-172.

18. Ramsay SC, Weiller C, Myers R, et al. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet. 1992;339:1054-1055.

19. Züchter NR, Loggia ML, Mulliet JF, et al. [11C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Mol Psychiatry. Epub 2020 19 Feb doi:10.1038/s41380-020-0682-z.

20. Burgos N, Cardoso MJ, Thielemans K, et al. Attenuation correction synthesis for hybrid PET-MR scanners: application to brain studies. IEEE Trans Med Imaging. 2014;33:2332-2341.

21. Manavaki R, Hong YT, Fryer TD. Brain MRI Coil Attenuation Map Processing for the GE SIGMA PET/MR: Impact on PET Image Quantification and Uniformity. 2019 IEEE Nucl Sci Symp Med Imaging Conf NSS/MIC. 2019.

22. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.

23. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12:6-26.

24. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904-911.

25. Tomasi G, Edison P, Bertoldo A, et al. Novel reference region model reveals increased microglial and reduced vascular binding of [11C]-PK11195 in patients with Alzheimer’s disease. J Nucl Med. 2008;49:1249-1256.

26. Yasub M, Van Berckel BNM, Schuitemaker A, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in [11C]-PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600-1608.

27. Syropoulos A, Manford M, Horvath R, et al. Near-identical segregation of mtDNA heteroplasmy in blood, muscle, urinary epithelium, and hair follicles in twins with optic atrophy, ptosis, and intractable epilepsy. JAMA Neurol. 2013;70:1552-1555.

28. Martikainen MH, Ng YS, Gorman GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol. 2016;73:668-674.

29. Schmitz-Hübsch T, Du Moustet ST, Bäko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(6):1717-1720.

30. Collette K, Plavén-Sigray P, Fautours-Bergman H, et al. Lower levels of the glial cell marker TSPO in drug-naïve first-episode psychosis patients as measured using PET and [11 C]PBR28. Mol Psychiatry. 2017;22:850-856.

31. Debyeucy JC, Verspoor, J Van Laere KJ, et al. PET visualisation of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Nucl Med Mol Imaging. 2003;10:257-264.

32. Bets J, Jarvis E, Perry RH, et al. Molecular neuropathology of MELAS: level of heteroplasmy in individual neurons and evidence of extensive vascular involvement. Neuropathol Appl Neurol Biol. 2006;32:359-373.

33. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry. 1951;14:216-221.

34. Bardosi A, Creatzfeld F, DiMauro S, et al. Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase: a new mitochondrial multisystem disorder. Acta Neuropathol. 1987;49:248-258.

35. Sirotti A, Sule N, Adesina AM, et al. Increased blood-brain barrier permeability with inflammation in psychiatry. Trends Pharmacol Sci. 2018;23:143-149.

36. Sterky FH, Lee S, Wilborn R, Olson L, Larsson NG. Impaired mitochondrial transport and function as a biomarker of neuroinflammation in psychiatry. Mol Psychiatry. 2018;23:36-47.

37. Züchter NR, Loggia ML, Mulliet JF, et al. [11C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Mol Psychiatry. Epub 2020 19 Feb doi:10.1038/s41380-020-0682-z.

38. Burgos N, Cardoso MJ, Thielemans K, et al. Attenuation correction synthesis for hybrid PET-MR scanners: application to brain studies. IEEE Trans Med Imaging. 2014;33:2332-2341.

39. Tomasi G, Edison P, Bertoldo A, et al. Novel reference region model reveals increased microglial and reduced vascular binding of [11C]-PK11195 in patients with Alzheimer’s disease. J Nucl Med. 2008;49:1249-1256.

40. Yasub M, Van Berckel BNM, Schuitemaker A, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in [11C]-PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600-1608.
41. Dölle C, Flanes I, Nido GS, et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016;7:13548.
42. van den Ameele J, Li AYZ, Ma H, Chinnery PF. Mitochondrial heteroplasmy beyond the oocyte bottleneck. Semin Cell Dev Biol. 2020;97:156-166.
43. Chinnery PF, Samuels DC. Relaxed replication of mtDNA: a model with implications for the expression of disease. Am J Hum Genet. 1999;64:1158-1165.
44. Müller-Höcker J, Seibel P, Schneiderbanger K, Kadenbach B. Different in situ hybridization patterns of mitochondrial DNA in cytochrome c oxidase-deficient extraocular muscle fibres in the elderly. Virchows Arch A Pathol Anat Histopathol. 1993;422:7-15.
45. Batarseh A, Papadopoulos V. Regulation of translocator protein 18kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. 2010;327:1-12.
46. Lax NZ, Campbell GR, Reeve AK, et al. Loss of myelin-associated glycoprotein in Kearns-Sayre syndrome. Arch Neurol. 2012;69:490-499.
47. Gropman AL. Neuroimaging in mitochondrial disorders. Neurotherapeutics. 2013;10:273-285.
48. Lax NZ, Hepplewhite PD, Reeve AK, et al. Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study. J Neuropathol Exp Neurol. 2012;71:148-161.
49. Gao Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage. 2012;60:902-910.
50. Owen DRJ, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24-32.
51. Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158-167.
[11C]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease
Jelle van den Ameele, Young T. Hong, Roido Manavaki, et al.
Neurology 2021;96:e2761-e2773 Published Online before print April 21, 2021
DOI 10.1212/WNL.0000000000012033

This information is current as of April 21, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/96/22/e2761.full

References
This article cites 50 articles, 11 of which you can access for free at:
http://n.neurology.org/content/96/22/e2761.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Class III
http://n.neurology.org/cgi/collection/class_iii
Mitochondrial disorders
http://n.neurology.org/cgi/collection/mitochondrial_disorders

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise